The Duke Division of Hematology is actively involved in clinical research that translates to advances and improvements in clinical care for patients with benign and malignant blood-related disorders.
Clinical research is being conducted in the following areas:
Current Clinical Trials
Myeloproliferate Neoplasms
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
ClinicalTrials.gov Identifier: NCT01259856
Principal Investigator: Murat Arcasoy, MD
Contact: Murat Arcasoy, MD, 919-668-6309, arcas001@mc.duke.edu
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
ClinicalTrials.gov Identifier: NCT00665067
Principal Investigator: Murat Arcasoy, MD
Contact: Murat Arcasoy, MD 919-668-6309 arcas001@mc.duke.edu
Apheresis Program
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
ClinicalTrials.gov Identifier: NCT01554514
Principal Investigator: Ara Metjian, MD
Contact: Betty H Thames, RN, BSN 919-681-9564 elizabeth.thames@duke.edu
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
ClinicalTrials.gov Identifier: NCT02222545
Principal Investigator:
Contact: Angela Braswell (Pager) 970-6134
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
ClinicalTrials.gov Identifier: NCT02553317
Principal Investigator:
Contact: Kristine Byrne 919-681-2668
Hemostasis and Thrombosis
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome (APS)
ClinicalTrials.gov Identifier: NCT00482794
Principal Investigator: Thomas L. Ortel, MD, PhD
Contact: Thomas L. Ortel, MD, PhD, 919-684-5350 - thomas.ortel@duke.edu
EINSTEIN Junior Phase III: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)
ClinicalTrials.gov Identifier: NCT02234843
Principal Investigator:
Contact: Shelia Lambert-Adams 919-970-0654
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)
ClinicalTrials.gov Identifier: NCT02111564
Principal Investigator: Carmelo Graffignino/Thomas Ortel
Contact: Betty Thames - 970-0331
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
ClinicalTrials.gov Identifier: NCT02610127
Principal Investigator:
Contact: Kristen Mcgill 919-681-3565
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
ClinicalTrials.gov Identifier: NCT02303431
Principal Investigator:
Contact: Kristine Byrne 919-681-2668
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
ClinicalTrials.gov Identifier: NCT02427217
Principal Investigator:
Sickle Cell Disease
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
ClinicalTrials.gov Identifier: NCT02187003
Principal Investigator:
Contact: Angela Braswell 919-970-6134, Marilyn Telen, MD 919-684-5378 marilyn.telen@dm.duke.edu